Altered immune function in unaffected first-degree biological relatives of schizophrenia patients

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 1022-1025

  Martínez Gras, Isabel ^a,b,c   García Sánchez, Fernando ^d   Guaza, Carmen ^f   Rodríguez Jiménez, Roberto ^a,b,c   Andrés Esteban, Eva ^e   Palomo, Tomás ^a,b,c   Rubio, Gabriel ^a,b,c   Borrell, Jose ^f  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL DE MÓSTOLES   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f INSTITUTO CAJAL   (Spain)

Author keywords

Biomarker; Cytokine; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BROTHER; CAUCASIAN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FATHER; FIRST DEGREE RELATIVE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; NUCLEAR FAMILY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ADULT; AGED; BIOLOGICAL MARKERS; CYTOKINES; FAMILY; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 84872399927     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.05.036     Document Type: Article

References (24)

1. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophrenia Research 1999, 37:97-106.
2. American Psychiatric Association, 2000. Diagnostic and statistical manual of mental disorders (Revised 4th ed.), Washington, DC.
3. Arolt V., Weitzsch C., Wilke I., Nolte A., Pinnow M., Rothermundt M., Kirchner H. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Research 1997, 66(2-3):145-152.
4. Fan X.D., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Research 2007 2007, 149(1-3):267-271.
5. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia Bulletin 2009, 35(3):528-548.
6. Gaughran F., O'Neill E., Sham P., Daly R.J., Shanahan F. Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophrenia Research 2002, 56(3):235-239.
7. Kinney D.K., Hintz K., Shearer E.M., Barch D.H., Riffin C., Whitley K., Butler R.A. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Medical Hypotheses 2010, 74(3):555-563.
8. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research 1995, 29:141-152.
9. Mailian K.R., Boiadzhian A.S., Sogoian A.F., Sim B., Manukian L.A. Concentration and protein composition of circulating immune complexes in the blood of patients with schizophrenia and subjects with positive familial history of disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova105 2005, 4:55-60.
10. Martínez-Gras I., Pérez-Nievas B.G., García-Bueno B., Madrigal J.L., Andrés-Esteban E., Rodríguez-Jiménez R., Hoenicka J., Palomo T., Rubio G., Leza J.C. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPAR gamma are decreased in schizophrenia. Schizophrenia Research 2011, 128(1-3):15-22.
11. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70(7):663-667.
12. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences 2009, 63(3):257-265.
13. Müller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia. An integrative view. Annals of the New York Academy of Sciences 2000, 917:456-467.
14. Müller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Research 2006, 10(2):131-148.
15. Nunes S.O., Matsuo T., Kaminami M.S., Watanabe M.A., Reiche E.M., Itano E.N. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophrenia Research 2006, 84(1):180-182.
16. Pollmächer T., Haack M., Schuld A., Graus T., Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. Journal of Psychiatric Research 2000, 34:369-382.
17. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update. Molecular Psychiatry 2005, 10:434-449.
18. Sirota P. Increased anti-Sm antibodies in schizophrenic patients and their families. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1993, 17(5):793-800.
19. Sirota P., Meiman M., Herschko R., Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Research 2005, 134:151-159.
20. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. Journal of Autoimmunity 2006, 27(2):71-80.
21. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophrenia Research 2008, 102(1-3):1-18.
22. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
23. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry and Clinical Neurosciences 2010, 64:217-230.
24. Wright P., Sham P.C., Gilvarry C.M., Jones P.B., Cannon M., Sharma T., Murray R.M. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophrenia Research 1996, 20:261-287.